U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C10H15NO
Molecular Weight 165.2322
Optical Activity ( + )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PSEUDOEPHEDRINE

SMILES

CN[C@@H](C)[C@@H](O)C1=CC=CC=C1

InChI

InChIKey=KWGRBVOPPLSCSI-WCBMZHEXSA-N
InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10+/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12373557 | http://www.mayoclinic.org/drugs-supplements/ephedra--ma-huang/background/hrb-20059270 | https://www.sudafed.com/adult-products/congestion/sudafed-24-hour#uses-and-directions | https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0011888 | https://www.ncbi.nlm.nih.gov/pubmed/11772135 | https://www.ncbi.nlm.nih.gov/pubmed/10449190 | https://www.ncbi.nlm.nih.gov/pubmed/12954796

Pseudoephedrine is a sympathomimetic drug. Pseudoephedrine acts as an adrenomimetic and inhibitor of monoamine transporters. Ephedra sinica, a species of ephedra (ma huang), contains ephedrine and pseudoephedrine. Ephedra has been found to stimulate the nervous system, increase airflow into the lungs and constrict blood vessels. In combination with caffeine, ephedra appears to cause weight loss. Pseudoephedrine is a decongestant that shrinks blood vessels in the nasal passages. Pseudoephedrine is used to relieve nasal or sinus congestion caused by the common cold, sinusitis, and hay fever and other respiratory allergies.

CNS Activity

Originator

Ladenburg, A.
4
Sources: A. Ladenburg, C. Oelschlägel, Ber. 22, 1823 (1889).
Curator's Comment: (+)-threo-isomer of ephedrine, q.v. Isoln from E. vulgaris: A. Ladenburg, C. Oelschlägel, Ber. 22, 1823 (1889). Synthesis: E. Späth, R. Göhring, Monatsh. Chem. 41, 319 (1920). reference retrieved from http://www.drugfuture.com/chemdata/pseudoephedrine.html

Approval Year

1961
146
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 5.6 µM [IC50]
Inhibitor
8297
 1.18 µM [IC50]
Agonist
2678
Agonist
2678
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
SUDAFED 24 HOUR

Approved Use

temporarily relieves nasal congestion due to the common cold, hay fever or other upper respiratory allergies; reduces swelling of nasal passages; relieves sinus pressure

Launch Date

1992
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
292 ng/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/073585Orig1s000.pdf
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PSEUDOEPHEDRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4346 ng × h/mL
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/073585Orig1s000.pdf
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PSEUDOEPHEDRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.3 h
OTHER GOV
https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/073585Orig1s000.pdf
120 mg single, oral
dose: 120 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PSEUDOEPHEDRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
unknown, 16 years
n = 1
Health Status: unknown
Age Group: 16 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
Other AEs: Rhabdomyolysis, Creatine kinase increased...
Other AEs:
Rhabdomyolysis (1 patient)
Creatine kinase increased (1 patient)
Blood myoglobin increased (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Other AEs: Tension, Dry mouth...
Other AEs:
Tension (10 patients)
Dry mouth (6 patients)
Tachycardia (9 patients)
Palpitations (10 patients)
Anxiety (13 patients)
Insomnia (12 patients)
Anorexia (7 patients)
Restlessness (10 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
90 mg 1 times / day multiple, oral
Overdose
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18365604
unhealthy, 3 years
n = 1
Health Status: unhealthy
Age Group: 3 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/18365604
Disc. AE: Urinary retention...
AEs leading to
discontinuation/dose reduction:
Urinary retention (acute, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18365604
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 37 years
n = 1
Health Status: unhealthy
Condition: sinusitis
Age Group: 37 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
720 mg 1 times / day multiple, oral
Highest studied dose
Dose: 720 mg, 1 times / day
Route: oral
Route: multiple
Dose: 720 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/23918202
unhealthy, 38.8 years
n = 38
Health Status: unhealthy
Age Group: 38.8 years
Sex: M+F
Population Size: 38
Sources:
https://pubmed.ncbi.nlm.nih.gov/23918202
Sources:
https://pubmed.ncbi.nlm.nih.gov/23918202
30 mg 3 times / day multiple, oral
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 44 years
n = 1
Health Status: unhealthy
Condition: upper airway infection
Age Group: 44 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
120 mg 1 times / day multiple, oral
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 46 years
n = 1
Health Status: unhealthy
Condition: chronic sinusitis | allergic rhinitis
Age Group: 46 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
chlorpheniramine maleate(2 mg; twice daily, oral)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 50 years
n = 1
Health Status: unhealthy
Condition: rhinitis
Age Group: 50 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Disc. AE: Ischemic colitis, Abdominal pain...
AEs leading to
discontinuation/dose reduction:
Ischemic colitis (1 patient)
Abdominal pain (acute, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
720 mg single, oral
Overdose
Dose: 720 mg
Route: oral
Route: single
Dose: 720 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/18608273
unhealthy, 87 years
n = 1
Health Status: unhealthy
Age Group: 87 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/18608273
Other AEs: Hypertension...
Other AEs:
Hypertension (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/18608273
AEs

AEs

AESignificanceDosePopulation
Blood myoglobin increased 1 patient
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
unknown, 16 years
n = 1
Health Status: unknown
Age Group: 16 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
Creatine kinase increased 1 patient
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
unknown, 16 years
n = 1
Health Status: unknown
Age Group: 16 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
Rhabdomyolysis 1 patient
1500 mg single, oral
Overdose
Dose: 1500 mg
Route: oral
Route: single
Dose: 1500 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
unknown, 16 years
n = 1
Health Status: unknown
Age Group: 16 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/19006543
Palpitations 10 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Restlessness 10 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Tension 10 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Insomnia 12 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Anxiety 13 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Dry mouth 6 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Anorexia 7 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Tachycardia 9 patients
150 mg 2 times / day multiple, oral
Highest studied dose
Dose: 150 mg, 2 times / day
Route: oral
Route: multiple
Dose: 150 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
healthy, 24 years
n = 17
Health Status: healthy
Age Group: 24 years
Sex: M
Population Size: 17
Sources:
https://pubmed.ncbi.nlm.nih.gov/729619
Urinary retention acute, 1 patient
Disc. AE
90 mg 1 times / day multiple, oral
Overdose
Dose: 90 mg, 1 times / day
Route: oral
Route: multiple
Dose: 90 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/18365604
unhealthy, 3 years
n = 1
Health Status: unhealthy
Age Group: 3 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/18365604
Ischemic colitis 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 37 years
n = 1
Health Status: unhealthy
Condition: sinusitis
Age Group: 37 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Abdominal pain acute, 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 37 years
n = 1
Health Status: unhealthy
Condition: sinusitis
Age Group: 37 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Ischemic colitis 1 patient
Disc. AE
30 mg 3 times / day multiple, oral
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 44 years
n = 1
Health Status: unhealthy
Condition: upper airway infection
Age Group: 44 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Abdominal pain acute, 1 patient
Disc. AE
30 mg 3 times / day multiple, oral
Dose: 30 mg, 3 times / day
Route: oral
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 44 years
n = 1
Health Status: unhealthy
Condition: upper airway infection
Age Group: 44 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Ischemic colitis 1 patient
Disc. AE
120 mg 1 times / day multiple, oral
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 46 years
n = 1
Health Status: unhealthy
Condition: chronic sinusitis | allergic rhinitis
Age Group: 46 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Abdominal pain acute, 1 patient
Disc. AE
120 mg 1 times / day multiple, oral
Dose: 120 mg, 1 times / day
Route: oral
Route: multiple
Dose: 120 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 46 years
n = 1
Health Status: unhealthy
Condition: chronic sinusitis | allergic rhinitis
Age Group: 46 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Ischemic colitis 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
chlorpheniramine maleate(2 mg; twice daily, oral)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 50 years
n = 1
Health Status: unhealthy
Condition: rhinitis
Age Group: 50 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Abdominal pain acute, 1 patient
Disc. AE
30 mg 2 times / day multiple, oral
Dose: 30 mg, 2 times / day
Route: oral
Route: multiple
Dose: 30 mg, 2 times / day
Co-administed with::
acetominophen(500 mg twice daily, oral)
chlorpheniramine maleate(2 mg; twice daily, oral)
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
unhealthy, 50 years
n = 1
Health Status: unhealthy
Condition: rhinitis
Age Group: 50 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/10484004
Hypertension 1 patient
720 mg single, oral
Overdose
Dose: 720 mg
Route: oral
Route: single
Dose: 720 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/18608273
unhealthy, 87 years
n = 1
Health Status: unhealthy
Age Group: 87 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/18608273
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:51209
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:51209
ZINC
ZINC000000020259
http://zinc15.docking.org/substances/ZINC000000020259
eMolecules
494893
https://www.emolecules.com/cgi-bin/more?vid=494893
PubMed

PubMed

TitleDatePubMed
A Double-blind crossover trial of pseudoephedrine and triprolidine, alone and in combination, for the treatment of allergenic rhinitis.
1975 Jan
Recurrent ischaemic colitis associated with pseudoephedrine use.
2001 Apr
Chromatographic analysis of phenethylamine-antihistamine combinations using C8, C18 or cyano columns and micellar sodium dodecyl sulfate-pentanol mixtures.
2001 Apr
Angle closure risk from proprietary medicines.
2001 Apr
Study on the chiral recognition of the enantiomers of ephedrine derivatives with neutral and sulfated heptakis(2,3-O-diacetyl)-beta-cyclodextrins using capillary electrophoresis, UV, nuclear magnetic resonance spectroscopy and mass spectrometry.
2001 Apr 20
Aziridine ring-opening reactions with chiral enolates. Stereocontrolled synthesis of 5-substituted-3-methyl-pyrrolidin-2-ones.
2001 Aug 24
Effect of organic cations on the renal tubular secretion of pseudoephedrine in the rat.
2001 Jan-Feb
[Cost effectiveness of GM-CSF in the treatment of acute myeloblastic leukemia in aged patients: protocol of GOELAM Sa3].
2001 Mar-Apr
Comparative oral and topical decongestant effects of phenylpropanolamine and d-pseudoephedrine.
2001 Mar-Apr
Cardiovascular sympathomimetic amine interactions in rats treated with monoamine oxidase inhibitors and the novel oxazolidinone antibiotic linezolid.
2001 May
Chloroephedrine: contaminant of methamphetamine synthesis with cardiovascular activity.
2001 Nov 1
Acute psychosis due to the interaction of legal compounds--ephedra alkaloids in 'vigueur fit' tablets, caffeine in 'red bull' and alcohol.
2001 Oct
Relationship between expansion of the CAG repeat in exon 1 of the androgen receptor gene and idiopathic male infertility.
2001 Oct
Community pharmacists' experience of over-the-counter medicine misuse in Scotland.
2001 Sep
Time-controlled release pseudoephedrine tablets: bioavailability and in vitro/in vivo correlations.
2001 Sep
Separation and determination of ephedrine alkaloids and tetramethylpyrazine in Ephedra sinica Stapf by gas chromatography-mass spectrometry.
2001 Sep
Kinetic spectrophotometric methods for the quantitation of triprolidine in bulk and in drug formulations.
2001 Sep
Analysis of enantiomers giving partially overlapped peaks by using different treatments of the chromatographic ultraviolet signals: quantification of pseudoephedrine enantiomers.
2001 Sep 28
Simultaneous quantitation of ephedrines in urine by gas chromatography-nitrogen-phosphorus detection for doping control purposes.
2001 Sep 5
Myocardial infarction temporally related to ephedra--a possible role for the coronary microcirculation.
2002
[An open label multi-center clinical trial to evaluate the efficacy of compound pseudoephedrine [corrected] hydrochloride sustained release capsules in patients with nasal symptoms associated with common cold].
2002 Aug
Generalized dermatitis due to pseudoephedrine.
2002 Aug
Immediate hypersensitivity due to pseudoephedrine.
2002 Jan
Cerebral vasoconstriction and stroke after use of serotonergic drugs.
2002 Jan 8
Modifying the bitterness of selected oral pharmaceuticals with cation and anion series of salts.
2002 Jul
Erythrodermia to pseudoephedrine in a patient with contact allergy to phenylephrine.
2002 Jul-Aug
A comparative study of the side effects between pseudoephedrine in Loratadine plus Pseudoephedrine Sulfate Repetabs Tables and loratadine + pseudoephedrine tablet in treatment of allergic rhinitis in Thai patients.
2002 Jun
Pigmented purpuric dermatosis due to pseudoephedrine.
2002 May
Pseudoephedrine as a chiral auxiliary for asymmetric Michael reactions: synthesis of 3-aryl-delta-lactones.
2002 May 30
A moderate dose of pseudoephedrine does not alter muscle contraction strength or anaerobic power.
2002 Nov
Enhanced enantio- and diastereoselectivity via confinement and cation binding: yang photocyclization of 2-benzoyladamantane derivatives within zeolites.
2002 Nov 29
Quantitative and structural determination of pseudoephedrine sulfate and its related compounds in pharmaceutical preparations using high-performance liquid chromatography.
2002 Nov 7
[Blood supply of the lips].
2002 Oct
[Cutaneous complications following liver transplantation: epidemiologic and clinical study in 86 patients].
2002 Oct
[Toxic dermatitis caused by pseudoephedrine: apropos of a case].
2002 Sep
[Improving the medical treatment of minors who are victims of sexual assault or physical abuse: a receiving center and partnership between a psychiatric hospital and university hospital].
2003 Apr
Sensitive determination of ephedrine and pseudoephedrine by capillary electrophoresis with laser-induced fluorescence detection.
2003 Apr
Surfing, self-medicating and safety: buying non-prescription and complementary medicines via the internet.
2003 Apr
Controlled porosity osmotic pump-based controlled release systems of pseudoephedrine. I. Cellulose acetate as a semipermeable membrane.
2003 Apr 14
Separation and determination of ephedrine and pseudoephedrine by combination of flow injection with capillary electrophoresis.
2003 Jan
Physiological, subjective and performance effects of pseudoephedrine and phenylpropanolamine during endurance running exercise.
2003 Jan
Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs.
2003 Jul
Chiral analysis of amphetamine-type stimulants using reversed-polarity capillary electrophoresis/positive ion electrospray ionization tandem mass spectrometry.
2003 Jun
[Tobacco: knowledge, reasoning and opinion of high school students in Doubs. Reflections on prevention].
2003 Mar
Safety of selegiline with cold medications.
2003 Mar
Adrenaline given outside the context of life threatening allergic reactions.
2003 Mar 15
A comparative study of root canal preparation using FlexMaster and HERO 642 rotary Ni-Ti instruments.
2003 May
Canine model of nasal congestion and allergic rhinitis.
2003 May
Exemption of chemical mixtures containing the List I chemicals ephedrine, N-methylephedrine, N-methylpseudoephedrine, norpseudoephedrine, phenylpropanolamine, and pseudoephedrine. Final rule.
2003 May 1
Press-coating of immediate release powders onto coated controlled release tablets with adhesives.
2003 May 20
Patents

Patents

05560921
4
06835559
6
07888040
4
JP2002316927A
5
JP2002332229A
4
JP2003089638A
4
JP2007176958A
4
JP2007525670A
148
JP2008081510A
4
JP2008510795A
76
JP2010241834A
9
JP2010270109A
4
JP3553083B2
49
JPH02134A
4
JPS62221625A
4

Sample Use Guides

In Vivo Use Guide
SUDAFED® 24 HOUR TABLET, EXTENDED RELEASE; ORAL (PSEUDOEPHEDRINE HYDROCHLORIDE) 240MG adults and children 12 years and older: a tablet with water every 24 hours children under 12 years: do not use this product in children under 12 years of age
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Pseudoephedrine inhibits interleukin-2 (IL-2) and tumor necrosis factor (TNF) alpha-gene transcription in stimulated Jurkat cells, a human T-cell leukemia cell line.
Unknown
Name Type Language
PSEUDOEPHEDRINE
HSDB   INN   MART.   MI   VANDF   WHO-DD  
INN  
Official Name English
(1S,2S)-(+)-PSEUDOEPHEDRINE
Common Name English
(.ALPHA.S)-.ALPHA.-((1R)-1-(METHYLAMINO)ETHYL)BENZENEMETHANOL
Systematic Name English
(+)-(1S,2S)-PSEUDOEPHEDRINE
Common Name English
PSEUDOEPHEDRINE [VANDF]
Common Name English
EPHEDRINE HYDROCHLORIDE IMPURITY B [EP IMPURITY]
Common Name English
ACUNASO
Brand Name English
1-(S),2-(R)-ERYTHRO-(+)-EPHEDRINE
Common Name English
BENZENEMETHANOL, .ALPHA.-((1S)-1-(METHYLAMINO)ETHYL)-, (.ALPHA.S)-
Systematic Name English
pseudoephedrine [INN]
Common Name English
PSEUDOEPHEDRINE [HSDB]
Common Name English
(+)-THREO-EPHEDRINE
Common Name English
PSEUDOEPHEDRINE [MI]
Common Name English
PSEUDOEPHEDRINE [MART.]
Common Name English
Pseudoephedrine [WHO-DD]
Common Name English
ISOEPHEDRINE, D-
Common Name English
BENZENEMETHANOL, .ALPHA.-(1-(METHYLAMINO)ETHYL)-, (S-(R*,R*))-
Systematic Name English
(+)-PSEUDOEPHEDRINE
Common Name English
PSEUDOEPHEDRINE, (+)-
Common Name English
NEODURASINA
Brand Name English
Classification Tree Code System Code
WHO-VATC QR01BA02
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
CFR 21 CFR 119.1
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
WHO-VATC QR01BA52
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
NDF-RT N0000175552
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
NCI_THESAURUS C29709
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
CFR 21 CFR 1314.20
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
DEA NO. 8525
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
WHO-ATC R01BA02
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
LIVERTOX 813
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
NDF-RT N0000000209
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
WHO-ATC R01BA52
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
CFR 21 CFR 1315.13
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
Code System Code Type Description
CAS
90-82-4
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
PRIMARY
IUPHAR
7286
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
PRIMARY
EPA CompTox
DTXSID0023537
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
PRIMARY
EVMPD
SUB10157MIG
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
PRIMARY
DRUG BANK
DB00852
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
PRIMARY
RXCUI
8896
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
PRIMARY RxNorm
FDA UNII
7CUC9DDI9F
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
PRIMARY
INN
1061
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
PRIMARY
MESH
D054199
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
PRIMARY
LACTMED
Pseudoephedrine
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
PRIMARY
RXCUI
407885
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
ALTERNATIVE
NCI_THESAURUS
C61914
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
PRIMARY
MERCK INDEX
m9294
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
PRIMARY Merck Index
ECHA (EC/EINECS)
202-018-6
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
PRIMARY
CHEBI
51209
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
PRIMARY
ChEMBL
CHEMBL1590
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
PRIMARY
SMS_ID
100000085477
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
PRIMARY
WIKIPEDIA
PSEUDOEPHEDRINE
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
PRIMARY
HSDB
3177
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
PRIMARY
PUBCHEM
7028
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
PRIMARY
DAILYMED
7CUC9DDI9F
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
PRIMARY
DRUG CENTRAL
2326
Created by admin on Fri Dec 15 15:21:38 GMT 2023 , Edited by admin on Fri Dec 15 15:21:38 GMT 2023
PRIMARY
ACTIVE MOIETY
Structure of PSEUDOEPHEDRINE
METABOLITE (PARENT)
Structure of CATHINE, (±)-
SALT/SOLVATE (PARENT)
Structure of PSEUDOEPHEDRINE SULFATE
SALT/SOLVATE (PARENT)
Structure of PSEUDOEPHEDRINE TANNATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966